Fuad El-Hibri has a solid background in business, holding an MBA from Harvard Business School. He served as the CEO of Emergent Biosolutions from May 2004 until April 2022, and he briefly worked at Aptevo Therapeutics in 2022. El-Hibri led...

Fuad El-Hibri has a solid background in business, holding an MBA from Harvard Business School. He served as the CEO of Emergent Biosolutions from May 2004 until April 2022, and he briefly worked at Aptevo Therapeutics in 2022. El-Hibri led Emergent during crucial times, especially as the company expanded its offerings in public health and emergency response. His approach to compensation is focused on performance—he recently received around $1.07 million in total compensation for 2022, which was significantly influenced by the company’s performance metrics that fell short that year. Looking at his stock ownership, at the height of his wealth in 2020, his holdings reached approximately $954 million before falling sharply. His insider trading activities reflected this volatility, with significant changes evident from 2020 to 2023. El-Hibri knows how to navigate both challenges and opportunities in the biomedical space, reflecting a deep understanding of the industry's regulatory and competitive landscapes.